UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of (I.R.S. Emplo ...

This small-cap biotech stock is surging. Time to buy?Last Friday, Agenus (AGEN 40.84%), an immuno-oncology player, saw its shares soar by a staggering 40.8%. This remarkable rally occurred seemingly without a clear catalyst. The company is set to announce its first-quarter earnings for 2024 before the market opens on Tuesday, May 7. However, there's no certainty that the company will release any information that justifies this significant surge in its shares.So, what's causing all the excitement? Investors ...

Loading...Loading...The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of maj ...

Agenus (AGEN) shares rallied 6.8% in the last trading session to close at $5.31. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 55.8% loss over the past four weeks.Earlier this month, the company announced updated data from its phase I study evaluating the BOT/BAL combination therapy in patients with metastatic colorectal cancer that is not microsatellite instability-high (MSS) or deficient mismatch repair ( ...

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.The past nine months have been rough ones to be an Agenus (AGEN -0.43%) shareholder. The stock has collapsed by about 75% from the peak it set last June.Investment bank analysts on Wall Street who follow the Massachusetts-headquartered cancer drug developer think it's been underappreciated. For example, B. Riley recently reiterated a buy rating for Agenus with a $5 price target.Agenus shares could deliver an enormo ...

These stocks could rocket higher, but they also present significant risks.Investors looking for stocks that can produce dramatic gains over the next 12 months want to turn their attention to the biotechnology industry. Wall Street analysts tasked with following a synthetic biology company called Ginkgo Bioworks (DNA -6.25%) think it can more than double your money.Investment bankers also have high hopes for Agenus (AGEN -12.85%). The latest price targets on the cancer drug developer suggest it can shoot mor ...

Here’s the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I’m not just talking about the price of the securities themselves. Indeed, these lesser-known enterprises are relatively low priced.No, the cost comes in the fact that extreme speculation such as this involves an inverse relationship. For maximum potential upside, you typically need to absorb the minimal amount of predictability. Let’s consider blue-chip stocks. Generally, you can be profitable with these securit ...

Agenus Inc. (NASDAQ:AGEN) Q4 2023 Results Conference Call March 14, 2024 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and Chief Executive Officer Steven O'Day - Chief Medical Officer Christine Klaskin - VP, Finance and Principal Financial and Accounting Officer Todd Yancy - Chief Strategic Advisor Conference Call Participants Emily Bodnar - H.C. Wainright Mayank Mamtani - B. Riley Securities Colleen Kusy - Baird Matthew Phipps - William Blair Operator Good mo ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023. “In 2023, Agenus made significant advances across our BOT/BAL development program. Our first target indication is metastatic, refractory colorectal cancer that is not MSI-H/dMMR, for which we are focused on pursuing accelerated approva ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | --- | --- | |-------------------------------------------------------|---------------------------------------------------------------------------------------- ...